GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemagen Diagnostics Inc (OTCPK:HMGN) » Definitions » Cyclically Adjusted PS Ratio

Hemagen Diagnostics (Hemagen Diagnostics) Cyclically Adjusted PS Ratio : (As of Jun. 09, 2024)


View and export this data going back to . Start your Free Trial

What is Hemagen Diagnostics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hemagen Diagnostics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Hemagen Diagnostics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemagen Diagnostics Cyclically Adjusted PS Ratio Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hemagen Diagnostics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Hemagen Diagnostics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemagen Diagnostics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's Cyclically Adjusted PS Ratio falls into.



Hemagen Diagnostics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Hemagen Diagnostics's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2012 is calculated as:

For example, Hemagen Diagnostics's adjusted Revenue per Share data for the three months ended in Sep. 2012 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2012 (Change)*Current CPI (Sep. 2012)
=0.057/97.6331*97.6331
=0.057

Current CPI (Sep. 2012) = 97.6331.

Hemagen Diagnostics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200212 0.196 76.324 0.251
200303 0.203 77.716 0.255
200306 0.215 77.505 0.271
200309 0.225 78.138 0.281
200312 0.163 77.758 0.205
200403 0.198 79.066 0.244
200406 0.211 80.037 0.257
200409 0.167 80.121 0.204
200412 0.117 80.290 0.142
200503 0.131 81.555 0.157
200506 0.118 82.062 0.140
200509 0.134 83.876 0.156
200512 0.129 83.032 0.152
200603 0.124 84.298 0.144
200606 0.109 85.606 0.124
200609 -0.049 85.606 -0.056
200612 0.066 85.142 0.076
200703 0.111 86.640 0.125
200706 0.116 87.906 0.129
200709 -0.024 87.964 -0.027
200712 0.101 88.616 0.111
200803 0.118 90.090 0.128
200806 0.089 92.320 0.094
200809 0.111 92.307 0.117
200812 0.091 88.697 0.100
200903 0.085 89.744 0.092
200906 0.091 91.003 0.098
200909 0.088 91.120 0.094
200912 0.075 91.111 0.080
201003 0.092 91.821 0.098
201006 0.085 91.962 0.090
201009 0.086 92.162 0.091
201012 0.089 92.474 0.094
201103 0.079 94.283 0.082
201106 0.091 95.235 0.093
201109 0.074 95.727 0.075
201112 0.071 95.213 0.073
201203 0.072 96.783 0.073
201206 0.061 96.819 0.062
201209 0.057 97.633 0.057

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hemagen Diagnostics  (OTCPK:HMGN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Hemagen Diagnostics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Hemagen Diagnostics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemagen Diagnostics (Hemagen Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.
Executives
Howard F Curd director

Hemagen Diagnostics (Hemagen Diagnostics) Headlines

No Headlines